Beyond Parkinson’s disease: expanding the neurodegenerative spectrum of GBA1- associated disorders
This study expands the phenotypic spectrum of *GBA1*-associated disorders beyond Parkinson's disease by identifying a cohort of patients with atypical parkinsonism and multisystem features, revealing that complex genetic architectures involving multiple variants and co-occurring pathogenic mutations likely drive these heterogeneous neurodegenerative phenotypes.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Parkinson's disease is a condition that slowly disrupts the brain's ability to control movement, causing tremors, stiffness, and slowness. For a long time, doctors viewed it as a sporadic illness, something that happened by chance to individuals without a clear family history. However, scientists have discovered that genetics play a much larger role than previously thought. One specific gene, called GBA1, has emerged as a major player. This gene provides instructions for building an enzyme that acts like a cellular recycling crew, breaking down waste materials inside the cell's storage compartments. When this gene has errors, the waste builds up, clogging the system. This clogging is linked to the death of brain cells and the development of Parkinson's. While it was known that people with two broken copies of this gene suffer from a severe condition called Gaucher disease, and that people with just one broken copy have a higher risk of Parkinson's, the full picture of what happens when this gene is involved remained incomplete.
A team of researchers in Italy set out to look beyond the standard definition of Parkinson's to see what else might be happening in patients with these genetic errors. They gathered a large group of 110 people who were struggling with complex neurological problems that did not fit neatly into a single diagnosis. These patients had symptoms ranging from movement issues to cognitive decline, but their conditions were often labeled as "atypical," meaning they were unusual or hard to categorize. The scientists wanted to know if the GBA1 gene was the sole cause of their suffering or if other genetic factors were working alongside it to create these difficult cases. By examining the DNA of this entire group, they hoped to uncover a more accurate map of how these genetic errors lead to disease.
The researchers found that the GBA1 gene was indeed involved, but not in the simple way often described. Out of the 110 patients, nine individuals carried a harmful error in one copy of the GBA1 gene. However, the story did not end there. When the scientists looked closer at the DNA of these nine patients, they discovered that the genetic landscape was far more complicated. Four of these patients carried two different errors on the same copy of the gene, a configuration that likely made the enzyme's job even harder. Furthermore, five of the nine patients had additional, rare errors in other genes that are also known to affect the brain, such as those involved in epilepsy or the movement of materials within cells. This suggests that for these patients, the disease was not caused by a single broken part, but by a combination of several genetic hits working together.
The symptoms these patients experienced were incredibly diverse, stretching far beyond the classic shaking and stiffness of Parkinson's. While some patients did show movement problems, many others suffered primarily from severe cognitive decline, psychiatric issues, or problems with the body's automatic functions like blood pressure and sleep. For instance, some patients had symptoms that looked more like other forms of dementia or rare neurological disorders than typical Parkinson's. One patient had a physical appearance resembling a specific connective tissue disorder, while another had a history of seizures. The researchers noted that patients with the most severe type of GBA1 error tended to have an earlier onset of symptoms and a faster decline, often developing dementia sooner than those with milder errors.
A key discovery in this study was the presence of these "double hits" in the DNA. In four of the patients, two different errors were found on the same gene strand. One of these errors was a small change in a part of the gene that had never been reported before, while another was a duplication of a section of the gene that had been missed by standard tests. The researchers confirmed this duplication using a specific laboratory test designed to count copies of DNA. These complex arrangements likely reduced the amount of working enzyme even further, contributing to the severe nature of the patients' conditions. Additionally, the finding that other genes were mutated in the same patients suggests that the brain's vulnerability is a cumulative effect. It is as if the GBA1 error lowers the brain's defenses, and when other genetic weaknesses are present, the system collapses more quickly and in more unpredictable ways.
The study also highlighted that the most common GBA1 errors found in the general population of Parkinson's patients were missing from this specific group. Instead, this cohort carried rarer, more severe errors. This distinction is important because it implies that the patients in this study represent a different, perhaps more complex, subset of the disease. Their conditions were characterized by a mix of movement disorders, cognitive loss, and problems affecting multiple body systems, such as the immune system or blood vessels. The researchers concluded that these patients should not be viewed simply as having a subtype of Parkinson's disease. Instead, they represent a broader spectrum of neurodegenerative disorders where the breakdown of cellular waste management interacts with other genetic factors to drive a wide variety of symptoms.
By identifying these complex genetic patterns, the researchers argue that doctors need to look deeper when diagnosing patients with atypical neurological symptoms. Relying only on the presence of movement issues or a single gene test might miss the full picture. The study suggests that understanding the combination of genetic errors is essential for improving diagnostic accuracy and, eventually, for developing treatments that target the specific weaknesses of each patient. The findings reinforce the idea that neurodegenerative diseases are not always caused by a single broken switch, but often by a complex web of genetic factors that, when combined, create a unique and challenging clinical picture. This work expands the known boundaries of GBA1-related disorders, showing that the consequences of this genetic error reach far beyond the traditional definition of Parkinson's disease.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.